I think you nailed it, most likely tying up loose ends…with no enrollment, this is a convenient step given Amarex is the collaborator…fool me twice, shame on me. Cytodyn will come back to this indication, it is on their priority roadmap for the future…I assume with a bigger/better collaborator and partner.